AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24950773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 120
Study 22421420 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide (S/N) anesthesia
Number of subjects: 40
Study 22421420 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil (P/R) anesthesia
Number of subjects: 40
Study 21153933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 10 mg 5% levobupivacaine + 0.1 mg morphine (Group M)
Number of subjects: 60
Study 21153933 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 10 mg 5% levobupivacaine + 20 mcg fentanyl (Group F)
Number of subjects: 60
Study 18487730 — intervention group
Group type: EXPERIMENTAL
Intervention: CARDSS guideline-based decision support system
Number of subjects: 63
Study 16002536 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethinyl oestradiol (EE) with cyproterone acetate (CA)
Number of subjects: 34
Study 16002536 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐oestradiol (E2) with cyproterone acetate (CA)
Number of subjects: 34
Study 16002536 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (CA) only
Number of subjects: 34
Study 16002536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone esters
Number of subjects: 34
Study 12540402 — intervention group
Group type: EXPERIMENTAL
Intervention: [(13)C]genistein
Number of subjects: 16
Study 12540402 — intervention group
Group type: EXPERIMENTAL
Intervention: [(13)C]daidzein
Number of subjects: 16
Study 12540402 — intervention group
Group type: EXPERIMENTAL
Intervention: Both [(13)C]daidzein and [(13)C]genistein
Number of subjects: 16
Study 10928760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C treated group (0.2 mg/mL for five minutes)
Number of subjects: 35
Study 10928760 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical excision alone)
Number of subjects: 35
Study 8822681 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 60mL saline and dextrose into the knee joint followed by submaximal exercise for 3 to 4 minutes
Number of subjects: 27
Study 8822681 — intervention group
Group type: COMPARATOR
Intervention: No injection of fluid, followed by submaximal exercise for 3 to 4 minutes
Number of subjects: 27
Study 8822681 — intervention group
Group type: COMPARATOR
Intervention: Three maximum effort tests without any intervention
Number of subjects: 27
Study 1424419 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg lansoprazole administered once daily for 10 days
Number of subjects: 12
Study 1424419 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered once daily for 10 days
Number of subjects: 12
Study 3457234 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Exercise (DE)
Number of subjects: 96
Study 3457234 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (D)
Number of subjects: 96
Study 3457234 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 96
Study 3457234 — intervention group
Group type: COMPARATOR
Intervention: Sedentary Control (C)
Number of subjects: 96
Study 29485326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (FAS)
Number of subjects: 20
Study 26150222 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 ablation
Number of subjects: 22
Study 26150222 — intervention group
Group type: COMPARATOR
Intervention: T2-T3 ablation
Number of subjects: 22
Study 23300301 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% whole yeast cell product (CitriStim) supplementation
Number of subjects: 0
Study 23300301 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole yeast cell product (CitriStim) supplementation
Number of subjects: 0
Study 21426372 — intervention group
Group type: COMPARATOR
Intervention: SB-656933 400 mg
Number of subjects: 0
Study 21426372 — intervention group
Group type: COMPARATOR
Intervention: SB-656933 50 mg
Number of subjects: 0
Study 21426372 — intervention group
Group type: COMPARATOR
Intervention: SB-656933 150 mg
Number of subjects: 0
Study 19628647 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus ramipril (combination therapy group)
Number of subjects: 97
Study 19628647 — intervention group
Group type: COMPARATOR
Intervention: Ramipril alone (monotherapy group)
Number of subjects: 97
Study 16765398 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sulfadoxine/pyrimethamine (single dose) and artesunate (3 daily doses of 4 mg/kg)
Number of subjects: 27
Study 16765398 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine and artesunate (3 daily doses)
Number of subjects: 27
Study 15633617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithuanian mariners with hypertension
Number of subjects: 0
Study 15633617 — intervention group
Group type: COMPARATOR
Intervention: General population of Lithuania
Number of subjects: 0
Study 15633617 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors associated with hypertension
Number of subjects: 0
Study 15633617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 0
Study 15633617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension with other risk factors
Number of subjects: 0
Study 11396558 — intervention group
Group type: EXPERIMENTAL
Intervention: Night vision goggles (NVG) at 3 or 10 footlamberts (fL)
Number of subjects: 0
Study 11396558 — intervention group
Group type: COMPARATOR
Intervention: Decrease in luminance levels below 0.03 fL
Number of subjects: 0
Study 9754844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (160 mg average daily dosage, highest permitted dose of 300 mg/day)
Number of subjects: 46
Study 9754844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7820711 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant treatment (Curosurf), dosage and duration not specified
Number of subjects: 253
Study 7820711 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate response to surfactant treatment
Number of subjects: 253
Study 3128137 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% Ventimask with 10 litres/minute oxygen flow
Number of subjects: 71
Study 3128137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula with 6 litres/minute oxygen flow
Number of subjects: 71
Study 3128137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula with 9 litres/minute oxygen flow
Number of subjects: 71
Study 3128137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson mask with 3 litres/minute oxygen flow
Number of subjects: 71
Study 3128137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson mask with 6 litres/minute oxygen flow
Number of subjects: 71
Study 3128137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson mask with 9 litres/minute oxygen flow
Number of subjects: 71
Study 3128137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula with 6 litres/minute humidified oxygen flow
Number of subjects: 71
Study 3128137 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% Ventimask
Number of subjects: 71
Study 3128137 — intervention group
Group type: COMPARATOR
Intervention: Unconscious state
Number of subjects: 71
Study 3128137 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 71
Study 31250126 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program based on the BASNEF model
Number of subjects: 120
Study 31250126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 120
Study 29192004 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive case management service (CCMS)
Number of subjects: 331
Study 29192004 — intervention group
Group type: COMPARATOR
Intervention: Usual care directed by their PCP
Number of subjects: 331
Study 25438965 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter intervention
Number of subjects: 12205
Study 25438965 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 12205
Study 23164308 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate CPAP
Number of subjects: 70
Study 23164308 — intervention group
Group type: COMPARATOR
Intervention: Delayed CPAP (1 hour after presentation)
Number of subjects: 70
Study 21594708 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) intravesical instillation within 24 hours of transurethral bladder resection (TURB)
Number of subjects: 211
Study 21594708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 211
Study 21594708 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) intravesical instillation
Number of subjects: 211
Study 21594708 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) treatment
Number of subjects: 211
Study 18455085 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 18455085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21900715 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction arm (IA): pegylated interferon-α2a 270 μg/week plus ribavirin 1,600 mg daily for 4 weeks, followed by pegylated interferon-α2a at standard dosages plus weight-based ribavirin for 8 weeks.
Number of subjects: 67
Study 21900715 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy arm (SA): pegylated interferon-α2a plus weight-based ribavirin for 12 weeks.
Number of subjects: 67
Study 21900715 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction arm (IA)
Number of subjects: 67
Study 21900715 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy arm (SA)
Number of subjects: 67
Study 16273807 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments from Swedish RA registry and biologics registries (ARTIS, SSATG, STURE)
Number of subjects: 0
Study 11840671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 37
Study 11840671 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/N2O (50 vol%)
Number of subjects: 37
Study 9814461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment during pregnancy
Number of subjects: 44
Study 9814461 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 44
Study 7897333 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial ECG findings in women
Number of subjects: 373
Study 2653552 — intervention group
Group type: EXPERIMENTAL
Intervention: Short overall treatment times (less than or equal to 4 weeks)
Number of subjects: 611
Study 2653552 — intervention group
Group type: COMPARATOR
Intervention: Long overall treatment times (greater than 4 weeks)
Number of subjects: 611
Study 355965 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ibuprofen
Number of subjects: 100
Study 355965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 29117309 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (daily capsule with 109 total colony-forming units of Bifidobacterium lactis CECT 8145, B longum CECT 7347, Lactobacillus casei CECT 9104)
Number of subjects: 50
Study 29117309 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (maltodextrin-only capsules)
Number of subjects: 50
Study 29117309 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 50
Study 29117309 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 26826677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to improve clinician communication skills
Number of subjects: 383
Study 26826677 — intervention group
Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 383
Study 26826677 — intervention group
Group type: COMPARATOR
Intervention: Follow-up characteristics
Number of subjects: 383
Study 24746581 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy for painful bone metastases
Number of subjects: 1157
Study 22511299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 293
Study 22511299 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 293
Study 20737519 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Panax ginseng (G115)
Number of subjects: 30
Study 20737519 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg Panax ginseng (G115)
Number of subjects: 30
Study 20737519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18788838 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg three times daily
Number of subjects: 244
Study 18788838 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg twice daily
Number of subjects: 244
Study 18788838 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 244
Study 15882219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-antimicrobial dose doxycycline (SDD) 20 mg twice daily with scaling and root planing (SRP)
Number of subjects: 392
Study 15882219 — intervention group
Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP)
Number of subjects: 392
Study 12851185 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly group exercise programme with ancillary home exercises
Number of subjects: 163
Study 12851185 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 163
Study 11026650 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α infusion without pretreatment
Number of subjects: 0
Study 11026650 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α infusion after acetylsalicylic acid pretreatment
Number of subjects: 0
Study 11026650 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α infusion after N(G)‐monomethyl‐L‐arginine pretreatment
Number of subjects: 0
Study 8690112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoplasmic aspiration before ICSI
Number of subjects: 58
Study 8690112 — intervention group
Group type: COMPARATOR
Intervention: No cytoplasmic aspiration before ICSI
Number of subjects: 58
Study 1880092 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (500 mg tds)
Number of subjects: 76
Study 1880092 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/Clavulanic acid (Augmentin; 750 mg tds)
Number of subjects: 76
Study 1880092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Augmentin (1.2 g 8 hourly for 3 days, followed by oral doses as above for 7 days)
Number of subjects: 76
Study 1880092 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 76
Study 1880092 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/Clavulanic acid (Augmentin)
Number of subjects: 76
Study 1880092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Augmentin
Number of subjects: 76
Study 7146263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam, 18 mg/day
Number of subjects: 80
Study 7146263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31158739 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive leaf tea (OLT)
Number of subjects: 57
Study 31158739 — intervention group
Group type: COMPARATOR
Intervention: Low-concentration olive leaf tea (LOLT)
Number of subjects: 57
Study 29101597 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.3 g/day n-3 PUFA supplements
Number of subjects: 44
Study 29101597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29101597 — intervention group
Group type: COMPARATOR
Intervention: 4.3 g/day n-3 PUFA supplements vs Placebo
Number of subjects: 44
Study 26756752 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and parenteral prophylaxis (1 g cefmetazole before and every 3 h during surgery plus 1 g oral kanamycin and 750 mg metronidazole twice on the day before surgery)
Number of subjects: 579
Study 26756752 — intervention group
Group type: COMPARATOR
Intervention: Parenteral prophylaxis alone (1 g cefmetazole before and every 3 h during surgery)
Number of subjects: 579
Study 26756752 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and parenteral prophylaxis
Number of subjects: 579
Study 26756752 — intervention group
Group type: COMPARATOR
Intervention: Parenteral prophylaxis alone
Number of subjects: 579
Study 24670025 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracycline (5 mL)
Number of subjects: 96
Study 24670025 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (5 mL)
Number of subjects: 96
Study 23000202 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-prednisone
Number of subjects: 221
Study 20172126 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative statin therapy
Number of subjects: 10061
Study 20172126 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 10061
Study 18981485 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐677, 25 mg, once daily
Number of subjects: 65
Study 18981485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 15979192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline, 50 mg/24 h
Number of subjects: 70
Study 15979192 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography and physical therapy (15 sessions of 1 W/cm2 on cervical trigger points)
Number of subjects: 70
Study 12439086 — intervention group
Group type: EXPERIMENTAL
Intervention: G(1): 8 x 60% T(max) at P(max), 1:2 work:recovery ratio
Number of subjects: 38
Study 12439086 — intervention group
Group type: EXPERIMENTAL
Intervention: G(2): 8 x 60% T(max) at P(max), recovery at 65% HR(max)
Number of subjects: 38
Study 12439086 — intervention group
Group type: EXPERIMENTAL
Intervention: G(3): 12 x 30 s at 175% PPO, 4.5-min recovery
Number of subjects: 38
Study 12439086 — intervention group
Group type: COMPARATOR
Intervention: G(CON): Control group
Number of subjects: 38
Study 12161053 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day losartan
Number of subjects: 33
Study 12161053 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/day fosinopril
Number of subjects: 33
Study 9802743 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg vitamin E for 6 months
Number of subjects: 21
Study 9802743 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 21
Study 8567766 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone agonist (GnRHa) 0.1 mg s.c.
Number of subjects: 210
Study 8567766 — intervention group
Group type: COMPARATOR
Intervention: Human chorionic gonadotrophin (HCG) 10,000 IU i.m.
Number of subjects: 210
Study 2763278 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical pleurodesis (tetracycline and 30% glucose)
Number of subjects: 20
Study 2763278 — intervention group
Group type: COMPARATOR
Intervention: Pleural drainage alone
Number of subjects: 20
Study 668773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 9
Study 668773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 9
Study 668773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg
Number of subjects: 9
Study 668773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 75 mg
Number of subjects: 9
Study 668773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (various doses)
Number of subjects: 9
Study 668773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31035960 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 19
Study 31035960 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 19
Study 28389484 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal frequency-modulated systems (FMs) used daily over 10 weeks by 4 patients (intervention care subjects)
Number of subjects: 9
Study 28389484 — intervention group
Group type: COMPARATOR
Intervention: Standard care received by 5 patients (standard care subjects)
Number of subjects: 9
Study 25842726 — intervention group
Group type: EXPERIMENTAL
Intervention: Short heating time length group (15 min of moxibustion therapy)
Number of subjects: 40
Study 25842726 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate heating time length group (30 min of moxibustion therapy)
Number of subjects: 40
Study 25842726 — intervention group
Group type: EXPERIMENTAL
Intervention: Long heating time length group (60 min of moxibustion therapy)
Number of subjects: 40
Study 25842726 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture group (control)
Number of subjects: 40
Study 23373762 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietary counselling
Number of subjects: 89
Study 23373762 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study 21330587 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention (6 hours of structured sessions and the opportunity to educate 3 peers)
Number of subjects: 342
Study 21330587 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (time-matched)
Number of subjects: 342
Study 21330587 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-driven intervention (experience of recruiting and educating peers)
Number of subjects: 342
Study 21994102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular gaze deviation (OGD) measurement in patients with acute ischemic stroke (Group 1)
Number of subjects: 116
Study 21994102 — intervention group
Group type: COMPARATOR
Intervention: Ocular gaze deviation (OGD) measurement in ambulatory outpatients (Group 2)
Number of subjects: 116
Study 21994102 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate and disconjugate gaze evaluation in both groups
Number of subjects: 116
Study 16907670 — intervention group
Group type: EXPERIMENTAL
Intervention: Undercorrected group (blurred by +0.50 D)
Number of subjects: 48
Study 16907670 — intervention group
Group type: COMPARATOR
Intervention: Fully corrected group
Number of subjects: 48
Study 15006188 — intervention group
Group type: EXPERIMENTAL
Intervention: APV/RTV 600/100 mg twice daily
Number of subjects: 35
Study 11709566 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (four cycles of fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 698
Study 11709566 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy (same regimen administered postoperatively)
Number of subjects: 698